lactoferrin and Psoriasis

Lactoferrin (LF), a non-haem iron binding glycoprotein, shares antimicrobial properties with innate immune system components influencing proinflammatory release of cytokines involved in psoriatic plaque development. The objective of the study was to verify if LF could provide a therapeutic application in psoriasis.. An open-label, two arms, 4-week trial was designed on 30 subjects affected by mild to moderate plaque psoriasis. All patients received oral bovine LF 100 mg. Fifteen patients (group A) were topically treated with 10% LF ointment, 15 patients (group B) with 20% LF ointment. All patients applied only ointment vehicle on contra lateral target lesion as intra-patient side to side control. Efficacy was assessed by Target Lesion Score.. Twenty-two patients completed the study. Improvement in elevation, redness and scaling was observed on LF treated psoriatic target lesions comparing to the controlateral controls (P<0.05). There was no additional efficacy for 20% versus 10% topical applications. Oral drug alone did not exert any improvement on the control plaques receiving topical placebo.. Our clinical results suggest that LF could be included as a possible safe topical therapeutic option in the treatment of psoriatic plaque.

Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Animals; Cytokines; Dermatologic Agents; Drug Administration Schedule; Elbow; Female; Follow-Up Studies; Humans; Knee; Lactoferrin; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome

XP-828L is a nutraceutical compound obtained by the extraction of a growth factors-enriched protein fraction from bovine milk. XP-828L may improve psoriasis.. An open-label study was performed to determine the efficacy, tolerability and safety of XP-828L in the treatment of plaque psoriasis.. Eleven adult patients with chronic, stable plaque psoriasis on 2% or more of body surface area (BSA) received 5 g of oral XP-828L twice daily for 56 days.. All 11 patients completed the 56 days of treatment. At day 28, 6 of the 11 patients showed a reduction in PASI score. At 56 days, seven subjects had a decrease in PASI score ranging from 9.5% to 81.3%. Eight (8) out of 11 patients agreed to participate in an additional 8-week extension treatment phase. Improvement of psoriasis was maintained during the extension period. No clinically significant adverse events or laboratory abnormalities occurred.. XP-828L may improve psoriasis in patients with mild-to-moderate psoriasis.

Topics: Administration, Oral; Adult; Aged; Female; Follow-Up Studies; Humans; Immunoglobulins; Informed Consent; Lactalbumin; Lactoferrin; Male; Middle Aged; Milk Proteins; Psoriasis; Time Factors; Treatment Outcome

Topics: Adult; Aged; Aged, 80 and over; Arthritis, Juvenile; Arthritis, Rheumatoid; Female; Ferritins; Humans; Iron; Iron-Regulatory Proteins; Iron-Sulfur Proteins; Lactoferrin; Male; Middle Aged; Osteoarthritis; Psoriasis; RNA-Binding Proteins; Synovial Fluid; Transferrin

We used a biotinylated antibody ELISA technique to measure plasma levels of lactoferrin (LF) and the LF content of peripheral blood PMN in 20 patients with psoriasis, 21 with eczema or other inflammatory skin conditions, 19 patients with malignant skin tumours and 20 healthy control individuals. In psoriasis, plasma LF levels were significantly increased compared with levels in the other skin conditions and in the healthy controls (P less than 0.01). Furthermore, in psoriasis the LF content of circulating PMN was decreased. These findings provide further evidence that in psoriasis systemic activation ('priming') of circulating PMN may take place.

Topics: Adult; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lactoferrin; Lactoglobulins; Male; Middle Aged; Neutrophils; Psoriasis

Scales from patients with nonpustular psoriasis were investigated for the presence of peptides capable of activating functional activities in human polymorphonuclear leukocytes (PMNL). Two compounds with similar molecular weight (12,500 and 15,000) were isolated which markedly stimulated PMNL functional activities including chemotaxis, generation of superoxide radical anion (O-2), and liberation of beta-glucuronidase as a marker enzyme. As revealed by ion-exchange and subsequent radioimmunoassay followed by chromatofocusing, one peptide proved to be the desarginated form of the complement split product C5ades arg. No C5a was detectable. As a second psoriatic scale chemotaxin we isolated an anionic neutrophil-activating peptide (ANAP) which shows a single isoelectric point at pH 6.8. This peptide shares some of the characteristics of epidermal cell-derived thymocyte-activating factor and interleukin 1 and, as shown by deactivation experiments, it cross-reacts with a monocyte-derived cytokine. The 2 newly described neutrophil-activating peptides (C5ades arg and ANAP) may play an important role in the psoriatic tissue reaction.

Topics: Cell Movement; Chemotactic Factors; Chemotaxis, Leukocyte; Chromatography, Gel; Chromatography, Ion Exchange; Complement C5; Complement C5a, des-Arginine; Glucuronidase; Humans; Interleukin-8; Isoelectric Focusing; Lactoferrin; Molecular Weight; Neutrophils; Peptides; Peroxidase; Psoriasis; Superoxides

The relationship between psoriasis and palmoplantar pustulosis (PPP) is uncertain, as is the role of the neutrophil granulocyte in these conditions. In a previous comparative study of the rate of polymorphonuclear leucocyte (PMN) phagocytosis of IgG- and IgG-C3b-coated particles, an increased uptake rate was found in both diseases. Further information on the in vivo activity of PMNs in these conditions may be obtainable by determining the level of lactoferrin (LF) in serum from such patients, since LF serves as a specific marker of the turnover and activity of the circulating pool of neutrophils. In this study on 19 patients with psoriasis and 20 patients with PPP, elevated levels of LF were found in both conditions. In contrast, the levels of lysozyme and beta 2-microglobulin, which are markers of monocyte-macrophage and lymphocyte activity, respectively, were normal. This suggests the selective activation of neutrophils in these disorders. LF was significantly correlated (P less than 0.05 and 0.001, respectively) to the rates of phagocytosis of IgG- and IgG-C3b-coated particles, but not to the chemotaxis of isolated PMNs. There was no correlation between the severity of the disease and the levels of serum LF. The data suggest the increased in vivo activity of neutrophils in psoriasis and PPP.

Topics: Adolescent; Adult; Aged; beta 2-Microglobulin; Chemotaxis, Leukocyte; Female; Foot Dermatoses; Hand Dermatoses; Humans; Lactoferrin; Male; Middle Aged; Muramidase; Neutrophils; Phagocytosis; Psoriasis; Suppuration